ArticleEuropean journal of nuclear medicine and molecular imaging2026
Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePSMA PET/MRI pairs high sensitivity for PSMA-avid lesions with superior soft-tissue contrast and provides quantitative metrics that may predict clinical outcomes of prostate cancer (PCa). We investigated whether intraprostatic PET-derived metrics and PSA-based variables predict histopathological ISUP grade and biochemical recurrence (BCR) after radical prostatectomy (RPE).
methodsMen with primary PCa who underwent [⁶⁸Ga]PSMA PET/MRI before RPE were retrospectively analyzed. PET-derived tumor metrics, initial PSA (iPSA), PSA density (PSAD), and ISUP grade were assessed for association with tumor aggressiveness and BCR. Discriminatory performance was evaluated using ROC AUCs. Multivariable logistic regression retained the better-performing variable within correlated pairs (e.g., SUVpeak vs. SUVmax). Kaplan–Meier and Cox models examined recurrence-free survival.
resultsAmong 101 men, all evaluated parameters differentiated low- (ISUP 1–2) from high-grade (ISUP 3–5) disease, with PET metrics showing the highest AUCs. In multivariable analysis, SUVpeak independently predicted high-grade disease (OR 1.3, 95% CI 1.1–1.5, p < 0.001). Follow-up was available for 71 patients (mean 3.2 ± 2.8 years); 36 (51%) developed BCR after 2.7 ± 2.6 years. For BCR prediction, all variables except SUVmax showed significant AUCs. In multivariable models, ISUP (OR 1.8, 95% CI 1.2–2.9, p = 0.01) and PSAD (OR 4.0, 95% CI 1.1–15.0, p = 0.039) remained significant. The combined model (ISUP + SUVpeak + PSAD) achieved an AUC of 0.788 (95% CI 0.678–0.898, p < 0.001). In Cox analysis, only high ISUP grade independently predicted time to BCR (HR 3.2, 95% CI 1.2–8.9, p = 0.02).
conclusionIntraprostatic PET metrics, especially SUVpeak, effectively assess tumor aggressiveness before RPE, while PSAD adds prognostic value for recurrence. Postoperative ISUP grade remains the strongest predictor of BCR. Combined imaging and PSA-based markers may improve risk stratification and warrant validation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.